Careers  |  Sign In  |  Register

Navigating New Immune-Based Combinations in Advanced NSCLC

Joshua K. Sabari, MD, assistant professor, Department of Medicine, NYU Langone Health’s Perlmutter Cancer Center, discusses the limited treatment options for non-small cell lung cancer (NSCLC) patients without known driver mutations. Dr. Sabari recommends pembrolizumab for patients with high PD-L1, while a combination of pembrolizumab and platinum-doublet chemotherapy is recommended for patients with low PD-L1. He also emphasizes the need for additional predictive biomarkers to identify subsets of patients who may benefit from alternative immune therapies.

Read more by clicking here.

Faculty

D. Ross Camidge, MD, PhD
D. Ross Camidge, MD, PhD

Professor, Medicine - Medical Oncology

University of Colorado Cancer Center

Anschutz Medical Campus

Erin Schenk, MD, PhD
Erin Schenk, MD, PhD

Assistant Professor, Medicine - Medical Oncology

University of Colorado Cancer Center

Anschutz Medical Campus